Novartis ( Novartis )

Novartis

Novartis's picture

About Novartis

We want to discover, develop and successfully market innovative products to prevent and cure diseases, to ease suffering and to enhance the quality of life.

Novartis press release, blog etc

09/17/2018 - 05:04 Launch of Alcon Experience Academy Reinforces Commitment to Training and Education for Eye Care Professionals
09/17/2018 - 02:48 World's largest Alzheimer's survey reveals most adults believe a cure will be developed in their lifetime
09/13/2018 - 05:09 Novartis real-world evidence confirms efficacy and safety benefits of Cosentyx in daily life for psoriasis patients
09/12/2018 - 16:26 Novartis announces NEJM publication of landmark PARADIGMS study demonstrating significant benefit of Gilenya in children and adolescents with MS
09/12/2018 - 15:58 Novartis survey shows psoriasis patients want treatment effect beyond clear skin
09/11/2018 - 16:57 Alcon confirms commitment to Switzerland ahead of proposed spinoff from Novartis
09/06/2018 - 08:47 Novartis to divest the Sandoz US dermatology business and generic US oral solids portfolio to Aurobindo
08/29/2018 - 04:06 Alcon announces voluntary global market withdrawal of CyPass Micro-Stent for surgical glaucoma
08/29/2018 - 03:47 European Commission approves Novartis combination therapy Tafinlar + Mekinist for adjuvant treatment of BRAF V600 mutation-positive melanoma
08/27/2018 - 04:20 Novartis receives European Commission approval of its CAR-T cell therapy, Kymriah (tisagenlecleucel)
08/25/2018 - 13:49 Novartis announces new data that show Entresto (sacubitril/valsartan) can be initiated early & safely in hospitalized patients after an acute heart failure episode
08/22/2018 - 23:26 SOLAR-1 trial of Novartis investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) meets primary endpoint in HR+/HER2- advanced breast cancer with PIK3CA mutation
08/14/2018 - 02:10 Novartis appoints Dr. Klaus Moosmayer as Chief Ethics Risk and Compliance Officer
07/30/2018 - 09:28 Novartis marks a new era for migraine patients with the EU approval of Aimovig, a first-of-its-kind treatment specifically designed for migraine prevention
07/27/2018 - 17:06 Novartis combination Tafinlar + Mekinist receives positive CHMP opinion for adjuvant treatment of BRAF V600 mutation-positive melanoma
07/27/2018 - 15:38 Sandoz receives European Commission approval for biosimilar Hyrimoz (adalimumab)
07/23/2018 - 01:19 Novartis renews drug donation of Egaten (triclabendazole) until 2022, reaffirming its commitment to the fight against liver fluke
07/19/2018 - 03:50 Novartis demonstrates commitment to lead immuno-dermatology by in-licensing IL-17C compound for atopic dermatitis